OPUS GENETICS, INC. US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 1501362 0 FOR 1501362 FOR SURROZEN, INC. US86889P2083 05/13/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 725372 0 FOR 725372 FOR SURROZEN, INC. US86889P2083 05/13/2026 Advisory vote on the preferred frequency of the advisory vote on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 725372 0 1 year 725372 FOR CELCUITY INC. US15102K1007 05/14/2026 To approve, on an advisory basis, named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 107603 0 FOR 107603 FOR NURIX THERAPEUTICS, INC. US67080M1036 05/15/2026 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 1 0 FOR 1 FOR CLENE INC. US1856342019 05/21/2026 Approval, on an advisory basis, of the compensation of our Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 409596 0 FOR 409596 FOR CORCEPT THERAPEUTICS INCORPORATED US2183521028 05/21/2026 To approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 104 0 FOR 104 FOR VIR BIOTECHNOLOGY, INC. US92764N1028 05/26/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 453836 0 FOR 453836 FOR FORTE BIOSCIENCES, INC. US34962G2084 05/29/2026 The approval, on an advisory basis, of the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025 (the "Say-on-Pay Vote"). SECTION 14A SAY-ON-PAY VOTES ISSUER 53239 0 FOR 53239 FOR PTC THERAPEUTICS, INC. US69366J2006 06/02/2026 Approval on a non-binding, advisory basis, of the Company's named executive officer compensation as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 2622 0 FOR 2622 FOR MOONLAKE IMMUNOTHERAPEUTICS KY61559X1045 06/04/2026 Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 266927 0 FOR 266927 FOR CAPRICOR THERAPEUTICS, INC. US14070B3096 06/04/2026 APPROVAL OF NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS SECTION 14A SAY-ON-PAY VOTES ISSUER 307060 0 FOR 307060 FOR CAPRICOR THERAPEUTICS, INC. US14070B3096 06/04/2026 APPROVAL OF FREQUENCY OF FUTURE NON-BINDING ADVISORY VOTES ON NAMED EXECUTIVE OFFICER COMPENSATION, ON A NON-BINDING ADVISORY BASIS SECTION 14A SAY-ON-PAY VOTES ISSUER 307060 0 1 year 307060 FOR TANGO THERAPEUTICS, INC. US87583X1090 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 9329723 0 FOR 9329723 FOR SAREPTA THERAPEUTICS, INC. US8036071004 06/04/2026 Advisory vote to approve, on a non-binding basis, named executive officer compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 76827 0 FOR 76827 FOR AMYLYX PHARMACEUTICALS, INC. US03237H1014 06/04/2026 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 50024 0 FOR 50024 FOR COGENT BIOSCIENCES, INC. US19240Q2012 06/09/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 41746 0 FOR 41746 FOR APOGEE THERAPEUTICS, INC. US03770N1019 06/09/2026 Approval, on a non-binding advisory basis, of the compensation of our named executive officers as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 115 0 FOR 115 FOR PALISADE BIO, INC. US6963894026 06/10/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 200002 0 FOR 200002 FOR SOLID BIOSCIENCES INC. US83422E2046 06/10/2026 The approval of an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 7946 0 FOR 7946 FOR UNIQURE N.V. NL0010696654 06/10/2026 Approval, on an advisory basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 1218417 0 FOR 1218417 FOR UNIQURE N.V. NL0010696654 06/10/2026 Approval, on an advisory basis, of the frequency of advisory votes on the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 1218417 0 1 year 1218417 FOR CORVUS PHARMACEUTICALS, INC. US2210151005 06/11/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 176670 0 FOR 176670 FOR VAXCYTE, INC. US92243G1085 06/15/2026 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 51518 0 FOR 51518 FOR STRUCTURE THERAPEUTICS, INC. US86366E1064 06/17/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 34042 0 FOR 34042 FOR PROTAGONIST THERAPEUTICS, INC. US74366E1029 06/17/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 98751 0 FOR 98751 FOR PRECIGEN, INC. US74017N1054 06/18/2026 Company Proposal - Advisory vote to approve executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 2159785 0 FOR 2159785 FOR REVOLUTION MEDICINES, INC. US76155X1000 06/18/2026 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). SECTION 14A SAY-ON-PAY VOTES ISSUER 37935 0 FOR 37935 FOR ORIC PHARMACEUTICALS, INC. US68622P1093 06/18/2026 To approve, on an advisory basis, executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 229 0 FOR 229 FOR ORIC PHARMACEUTICALS, INC. US68622P1093 06/18/2026 To approve, on an advisory basis, the frequency of future advisory votes on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 229 0 1 year 229 FOR UROGEN PHARMA LTD IL0011407140 06/22/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 178407 0 FOR 178407 FOR KYMERA THERAPEUTICS, INC. US5015751044 06/24/2026 To approve, on a non-binding advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 10017 0 FOR 10017 FOR Inovio Pharmaceuticals US45773H4092 05/20/2026 To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 2120122 0 FOR 2120122 FOR Karyopharm Therapeutics Inc. US48576U2050 05/21/2026 To approve, on an advisory basis, the compensation of our named executive officers, as described in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 302536 0 FOR 302536 FOR Cytokinetics, Incorporated US23282W6057 05/27/2026 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 100000 0 FOR 100000 FOR Regenxbio Inc. US75901B1070 05/29/2026 Advisory vote on the compensation paid to the Company's executive employees. SECTION 14A SAY-ON-PAY VOTES ISSUER 15000 0 FOR 15000 FOR Kodiak Sciences Inc. US50015M1099 06/02/2026 Approve, on an advisory basis, the compensation of Kodiak's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 284100 0 FOR 284100 FOR Crescent Biopharma, Inc. KYG2545C1042 06/02/2026 To approve, on a non-binding, advisory basis, the compensation of Crescent Biopharma, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 226843 0 FOR 226843 FOR Crescent Biopharma, Inc. KYG2545C1042 06/02/2026 To vote, on a non-binding advisory basis, on the frequency of future advisory votes to approve compensation for Crescent Biopharma, Inc.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 226843 0 1 year 226843 FOR Ocular Therapeutix, Inc. US67576A1007 06/10/2026 To approve an advisory vote on named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 1150000 0 FOR 1150000 FOR Ocular Therapeutix, Inc. US67576A1007 06/10/2026 To approve, on a non-binding, advisory basis, the frequency of future advisory votes to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 1150000 0 1 year 1150000 FOR ZYMEWORKS INC. US98985Y1082 12/30/2025 To approve, on an advisory basis, the compensation of our named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 NONE Kalvista Pharmaceuticals, Inc. US483497AA14 10/01/2025 To approve, on a non-binding advisory basis, the compensation paid by us to our named executive officers as disclosed in this proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 NONE Replimune Group, Inc. US76029N1063 09/03/2025 to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers for the fiscal year ended March 31, 2025 SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 NONE UROGEN PHARMA LTD IL0011407140 08/26/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 NONE UROGEN PHARMA LTD IL0011407140 08/26/2025 To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 NONE OPUS GENETICS, INC. US67577R1023 04/20/2026 Approval, on an advisory basis, of the compensation of the Company's named executive officers SECTION 14A SAY-ON-PAY VOTES ISSUER 0 0 0 NONE